Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - NPS Pharmaceuticals, Inc. (NasdaqNM:NPSP)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Recent Events
Aug  7Earnings Announcement
Location
420 Chipeta Way
Salt Lake City, UT 84108
Phone: (801) 583-4939
Fax: (801) 583-4961
Email: investor@npsp.com
Employees (last reported count): 136
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 29%
·Over the last 6 months:
 · one insider buy; 1,000  shares
 · 15 insider sells; 116.0K shares
  (1.3% of insider shares)
·Institutional: 81% (115% of float)
(224 institutions)
·Net Inst. Buying: 1.53M shares (+5.91%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
NPS Pharmaceuticals, Inc. is a biopharmaceutical company with headquarters in Salt Lake City, Utah, and additional operations in Toronto, Ontario, Canada. The Company discovers, develops and intends to commercialize small molecule drugs and recombinant proteins, primarily for bone and mineral disorders and central nervous system disorders. The Company has five drugs in clinical development and several preclinical product candidates. The Company's two most advanced product candidates focus on bone and mineral disorders. They are AMG 073, which has completed a series of Phase II clinical trials for treatment of hyperparathyroidism, and ALX1-11, which is in a pivotal Phase III clinical trial for treatment of post-menopausal osteoporosis.
More from Market Guide: Expanded Business Description

Financial Summary
NPSP is engaged in the discovery and development of prescription drugs that are intended to be active on selected biological targets, including ion channels, cell surface receptors and other metabolic pathways. For the six months ended 6/01, revenues decreased 76% to $982 thousand. Net loss before accounting change rose 23% to $22.2 million. Revenues reflect the expiration of R&D support payments. Higher loss also reflect increased research and development costs.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY1999 Compensation
PayExer

Hunter Jackson, Ph.D., 50
CEO, Pres and Chairman
$280K--  
Robert Merrell, 44
VP of Fin., CFO, and Treasurer
160K$204K
David Clark, 46
VP, Operations, Bus. Devel. and Corp. Communications
--  --  
James Jensen, 55
VP of Corp. Devel. and Legal Affairs Sec.,
188K--  
N. Patricia Freston, Ph.D., 60
VP of HR
--  --  
Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:NPSPAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$15.00 
Recent Price$33.62 
52-Week High
on 29-Sep-2000
$58.00 
Beta0.65 
Daily Volume (3-month avg)354.4K
Daily Volume (10-day avg)299.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-27.4%
52-Week Change
relative to S&P500
-2.6%
Share-Related Items
Market Capitalization$1.01B
Shares Outstanding30.0M
Float21.3M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$8.23 
Earnings (ttm)-$1.25 
Earnings (mrq)-$0.54 
Sales (ttm)$0.18 
Cash (mrq)$7.67 
Valuation Ratios
Price/Book (mrq)4.09 
Price/EarningsN/A 
Price/Sales (ttm)191.41 
Income Statements
Sales (ttm)$4.92M
EBITDA (ttm)-$44.9M
Income available to common (ttm)-$35.3M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-18.00%
Return on Equity (ttm)-18.50%
Financial Strength
Current Ratio (mrq)35.93 
Debt/Equity (mrq)0 
Total Cash (mrq)$230.3M
Short Interest
As of 8-Aug-2001
Shares Short1.53M
Percent of Float7.2%
Shares Short
(Prior Month)
1.87M
Short Ratio3.46 
Daily Volume442.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   B = billions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.